RxDoctor Payments Data

Brian Beluch, DO

Endocrinology, Diabetes & Metabolism · Doylestown, PANPI 1811142508

Payments from drug & device makers

$25,448in general payments, 2019–2025

Across 169 payments — averaging $150.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Medtronic$7K
  • Novo Nordisk$331
  • AstraZeneca$161
  • Insulet Corporation$121
  • Lilly USA, LLC$107
  • plus $359 from 13 others

What the payments were for

  • Consulting fees$6883%
  • Speaking & faculty fees$20,19479%
  • Travel & lodging$1,5076%
  • Food & beverage$3,03412%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,448 in reported general payments places this provider in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$218,264
Medicare patients
381
Services billed
5,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide184$319,031
JardianceEmpagliflozin185$219,546
TrulicityDulaglutide97$182,269
Tresiba Flextouch U-100Insulin Degludec137$111,224
MounjaroTirzepatide52$96,852
Humulin R U-500 KwikpenInsulin Regular, Human29$70,982
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/748$44,584
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$38,278
JanuviaSitagliptin Phosphate38$37,125
RybelsusSemaglutide31$37,037
TradjentaLinagliptin26$26,499
Novolog FlexpenInsulin Aspart74$21,836
NovologInsulin Aspart48$16,667
Humalog Kwikpen U-200Insulin Lispro11$13,242
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$12,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$331$372,735263 claims
Lilly USA, LLCTrulicity, Mounjaro$107$279,121149 claims
AbbVieSynthroid$16$5,05260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

Other endocrinology, diabetes & metabolism in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →